Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Рынки
Скринер
Новости
О нас

ETON - Eton Pharmaceuticals, Inc. Последние... | Finranks

Home

ETON

E

Eton Pharmaceuticals, Inc. (ETON)

NGM – Цена в реальном времени. Валюта: USD

23.24

-0.21 (-0.90%)

При закрытии: Mar 27, 2026, 4:00 PM EDT

23.24

0.00 (0.00%)

После закрытия: Mar 27, 2026, 5:20 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Eton Pharmaceuticals (ETON) Soars 6.7%: Is Further Upside Left in the Stock?

Eton Pharmaceuticals (ETON) Soars 6.7%: Is Further Upside Left in the Stock?

Eton Pharmaceuticals (ETON) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Recent Price Trend in Eton Pharmaceuticals (ETON) is Your Friend, Here's Why

Recent Price Trend in Eton Pharmaceuticals (ETON) is Your Friend, Here's Why

Eton Pharmaceuticals (ETON) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Does Eton Pharmaceuticals (ETON) Have the Potential to Rally 49.25% as Wall Street Analysts Expect?

Does Eton Pharmaceuticals (ETON) Have the Potential to Rally 49.25% as Wall Street Analysts Expect?

The mean of analysts' price targets for Eton Pharmaceuticals (ETON) points to a 49.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Eton Pharmaceuticals, Inc. (ETON) Q4 2025 Earnings Call Transcript

Eton Pharmaceuticals, Inc. (ETON) Q4 2025 Earnings Call Transcript

Eton Pharmaceuticals, Inc. (ETON) Q4 2025 Earnings Call Transcript

Eton Pharmaceuticals, Inc. (ETON) Q4 Earnings Lag Estimates

Eton Pharmaceuticals, Inc. (ETON) Q4 Earnings Lag Estimates

Eton Pharmaceuticals, Inc. (ETON) came out with quarterly earnings of $0.05 per share, missing the Zacks Consensus Estimate of $0.12 per share. This compares to a loss of $0.02 per share a year ago.

Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

DEER PARK, Ill., March 19, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the quarter ended December 31, 2025.

Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, March 19, 2026

Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, March 19, 2026

DEER PARK, Ill., March 03, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report fourth quarter and full year 2025 financial results on Thursday, March 19, 2026. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET (3:30 p.m. CT).

Видео

No Data

There is no data to display

Пресс-релизы

Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

DEER PARK, Ill., March 19, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the quarter ended December 31, 2025.

Eton Pharmaceuticals Expands Rare Disease Portfolio Through Acquisition of U.S. Commercialization Rights to HEMANGEOL® (propranolol hydrochloride) Oral Solution

Eton Pharmaceuticals Expands Rare Disease Portfolio Through Acquisition of U.S. Commercialization Rights to HEMANGEOL® (propranolol hydrochloride) Oral Solution

DEER PARK, Ill., March 02, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced it has in-licensed U.S. commercialization rights to HEMANGEOL® oral solution from Pierre Fabre Medicament Sas (“Pierre Fabre”). HEMANGEOL is an Orphan Drug indicated for the treatment of proliferating infantile hemangioma requiring systemic therapy.

Eton Pharmaceuticals Announces U.S. FDA Approval for DESMODA™ (desmopressin acetate) Oral Solution

Eton Pharmaceuticals Announces U.S. FDA Approval for DESMODA™ (desmopressin acetate) Oral Solution

DEER PARK, Ill., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the U.S. Food and Drug Administration (FDA) approval of a New Drug Application (NDA) for DESMODA™ (desmopressin acetate) Oral Solution for the management of central diabetes insipidus, also known as arginine vasopressin deficiency (AVP-D), as antidiuretic replacement therapy for patients of all ages.

Eton Pharmaceuticals Announces Licensing of Rare Disease Product Candidate

Eton Pharmaceuticals Announces Licensing of Rare Disease Product Candidate

DEER PARK, Ill., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the licensing of U.S. marketing rights to an ultra-rare disease product candidate. Once approved, the product is expected to be the first and only generic alternative to a product used to treat an ultra-rare condition that impacts fewer than 100 patients in the United States.